These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

239 related articles for article (PubMed ID: 12693735)

  • 1. Revisiting salt and water retention: new diuretics, aquaretics, and natriuretics.
    Costello-Boerrigter LC; Boerrigter G; Burnett JC
    Med Clin North Am; 2003 Mar; 87(2):475-91. PubMed ID: 12693735
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Brain natriuretic peptide enhances renal actions of furosemide and suppresses furosemide-induced aldosterone activation in experimental heart failure.
    Cataliotti A; Boerrigter G; Costello-Boerrigter LC; Schirger JA; Tsuruda T; Heublein DM; Chen HH; Malatino LS; Burnett JC
    Circulation; 2004 Apr; 109(13):1680-5. PubMed ID: 15023890
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The kidney in congestive heart failure: 'are natriuresis, sodium, and diuretics really the good, the bad and the ugly?'.
    Verbrugge FH; Dupont M; Steels P; Grieten L; Swennen Q; Tang WH; Mullens W
    Eur J Heart Fail; 2014 Feb; 16(2):133-42. PubMed ID: 24464967
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Chronic heart failure as a state of reduced effectiveness of the natriuretic peptide system: implications for therapy.
    Díez J
    Eur J Heart Fail; 2017 Feb; 19(2):167-176. PubMed ID: 27766748
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Natriuretic and antialdosterone actions of chronic oral NEP inhibition during progressive congestive heart failure.
    Martin FL; Stevens TL; Cataliotti A; Schirger JA; Borgeson DD; Redfield MM; Luchner A; Burnett JC
    Kidney Int; 2005 May; 67(5):1723-30. PubMed ID: 15840018
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Value of aldosterone receptor blockade in diuretic therapy of patients with chronic heart failure].
    Christ M; Ludwig N; Maisch B
    Herz; 2002 Mar; 27(2):135-49. PubMed ID: 12025459
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Diuretic therapy in congestive heart failure--new views on spironolactone therapy].
    Haller C
    Ther Umsch; 2000 Jun; 57(6):374-9. PubMed ID: 10894022
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Balancing diuretic therapy in heart failure: loop diuretics, thiazides, and aldosterone antagonists.
    Paul S
    Congest Heart Fail; 2002; 8(6):307-12. PubMed ID: 12461320
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rational use of diuretics in acute decompensated heart failure.
    Goebel JA; Van Bakel AB
    Curr Heart Fail Rep; 2008 Sep; 5(3):153-62. PubMed ID: 18752765
    [TBL] [Abstract][Full Text] [Related]  

  • 10. EFFECT OF AN ALDOSTERONE ANTAGONIST (SPIRONOLACTONE) ON PATIENTS WITH SEVERE CONGESTIVE HEART FAILURE.
    CARRUTHERS BM; LEDRAY RD; SERAGLIA M; MCINTOSH HW; WALSH GC
    Can Med Assoc J; 1963 Sep; 89(13):633-41. PubMed ID: 14077808
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Aldosterone antagonists in hypertension and heart failure.
    Mantero F; Lucarelli G
    Ann Endocrinol (Paris); 2000 Feb; 61(1):52-60. PubMed ID: 10790593
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of V2-receptor antagonist tolvaptan and the loop diuretic furosemide in rats with heart failure.
    Veeraveedu PT; Watanabe K; Ma M; Palaniyandi SS; Yamaguchi K; Kodama M; Aizawa Y
    Biochem Pharmacol; 2008 Mar; 75(6):1322-30. PubMed ID: 18179782
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Neurohumoral blockade in CHF management.
    Willenbrock R; Philipp S; Mitrovic V; Dietz R
    J Renin Angiotensin Aldosterone Syst; 2000 Sep; 1 Suppl 1():24-30. PubMed ID: 11967792
    [TBL] [Abstract][Full Text] [Related]  

  • 14. GLP-1 mediated diuresis and natriuresis are blunted in heart failure and restored by selective afferent renal denervation.
    Katsurada K; Nandi SS; Zheng H; Liu X; Sharma NM; Patel KP
    Cardiovasc Diabetol; 2020 May; 19(1):57. PubMed ID: 32384887
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Vasopressin-2-receptor antagonism augments water excretion without changes in renal hemodynamics or sodium and potassium excretion in human heart failure.
    Costello-Boerrigter LC; Smith WB; Boerrigter G; Ouyang J; Zimmer CA; Orlandi C; Burnett JC
    Am J Physiol Renal Physiol; 2006 Feb; 290(2):F273-8. PubMed ID: 16189291
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Angiotensin II AT1 receptor antagonism prevents detrimental renal actions of acute diuretic therapy in human heart failure.
    Chen HH; Redfield MM; Nordstrom LJ; Cataliotti A; Burnett JC
    Am J Physiol Renal Physiol; 2003 May; 284(5):F1115-9. PubMed ID: 12676739
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Aldosterone in congestive heart failure: analysis of determinants and role in sodium retention.
    Hensen J; Abraham WT; Dürr JA; Schrier RW
    Am J Nephrol; 1991; 11(6):441-6. PubMed ID: 1840232
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Urodilatin: a better natriuretic peptide?
    Vesely DL
    Curr Heart Fail Rep; 2007 Sep; 4(3):147-52. PubMed ID: 17883990
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Aldosterone and volume management in hypertensive heart disease.
    Sica DA
    Semin Nephrol; 2014 May; 34(3):323-32. PubMed ID: 25016402
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Determinants and impact of the natriuretic response to diuretic therapy in heart failure with reduced ejection fraction and volume overload.
    Verbrugge FH; Dupont M; Bertrand PB; Nijst P; Penders J; Dens J; Verhaert D; Vandervoort P; Tang WH; Mullens W
    Acta Cardiol; 2015 Jun; 70(3):265-73. PubMed ID: 26226699
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.